Circulating CD40 ligand is elevated only in patients with more advanced symptomatic peripheral arterial diseases

Thrombosis Research

Volumn 118, Issue 5, 2006, Pages 619-626

  Lee, Wen Jane ^a   Sheu, Wayne Huey Herng ^a,b   Chen, Ying Tsung ^a,b   Liu, Tsun Jui ^a,c   Liang, Kae Woei ^a,c   Ting, Chih Tai ^a,c   Lee, Wen Lieng ^a,c  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

CD40 ligand; hs CRP; Monocyte chemotactic protein 1; Peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; CD40 LIGAND; CLOPIDOGREL; MONOCYTE CHEMOTACTIC PROTEIN 1; TICLOPIDINE;

AGED; ANGIOGRAPHY; ARTERY DISEASE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; LEG; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SERUM; STENOSIS;

AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CD40 LIGAND; FEMALE; HUMANS; MALE; PERIPHERAL VASCULAR DISEASES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 33748764944     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.10.012     Document Type: Article

References (39)

1. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
2. Szmitko P.E., Wang C.H., Weisel R.D., Jeffries G.A., Anderson T.J., and Verma S. Biomarkers of vascular disease linking inflammation to endothelial activation: Part II. Circulation 108 (2003) 2041-2048
3. Szmitko P.E., Wang C.H., Weisel R.D., de Almeida J.R., Anderson T.J., and Verma S. New markers of inflammation and endothelial cell activation: Part I. Circulation 108 (2003) 1917-1923
4. Schonbeck U., and Libby P. CD40 signaling and plaque instability. Circ Res 89 (2001) 1092-1103
5. Andre P., Nannizzi-Alaimo L., Prasad S.K., and Phillips D.R. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106 (2002) 896-899
6. Mach F., Schonbeck U., Sukhova G.K., Bourcier T., Bonnefoy J.Y., Pober J.S., et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A 94 (1997) 1931-1936
7. Karmann K., Hughes C.C., Schechner J., Fanslow W.C., and Pober J.S. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci U S A 92 (1995) 4342-4346
8. Schonbeck U., and Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 58 (2001) 4-43
9. Mach F., Schonbeck U., Bonnefoy J.Y., Pober J.S., and Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 96 (1997) 396-399
10. Cipollone F., Marini M., Fazia M., Pini B., Iezzi A., Reale M., et al. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol 21 (2001) 327-334
11. Urbich C., Dernbach E., Aicher A., Zeiher A.M., and Dimmeler S. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation 106 (2002) 981-986
12. Aukrust P., Muller F., Ueland T., Berget T., Aaser E., Brunsvig A., et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100 (1999) 614-620
13. Cipollone F., Mezzetti A., Porreca E., Di Febbo C., Nutini M., Fazia M., et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 106 (2002) 399-402
14. Schonbeck U., Varo N., Libby P., Buring J., and Ridker P.M. Soluble CD40L and cardiovascular risk in women. Circulation 104 (2001) 2266-2268
15. Heeschen C., Dimmeler S., Hamm C.W., van den Brand M.J., Boersma E., Zeiher A.M., et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348 (2003) 1104-1111
16. Blann A.D., Tan K.T., Tayebjee M.H., Davagnanam I., Moss M., and Lip G.Y. Soluble CD40L in peripheral artery disease. Relationship with disease severity, platelet markers and the effects of angioplasty. Thromb Haemost 93 (2005) 578-583
17. Tsakiris D.A., Tschopl M., Wolf F., Labs K.H., Jager K.A., and Marbet G.A. Platelets and cytokines in concert with endothelial activation in patients with peripheral arterial occlusive disease. Blood Coagul Fibrinolysis 11 (2000) 165-173
18. Hiatt W.R. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 344 (2001) 1608-1621
19. Criqui M.H., Fronek A., Barrett-Connor E., Klauber M.R., Gabriel S., and Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 71 (1985) 510-515
20. Criqui M.H., Langer R.D., Fronek A., Feigelson H.S., Klauber M.R., McCann T.J., et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326 (1992) 381-386
21. Newman A.B., Shemanski L., Manolio T.A., Cushman M., Mittelmark M., Polak J.F., et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 19 (1999) 538-545
22. Henn V., Slupsky J.R., Grafe M., Anagnostopoulos I., Forster R., Muller-Berghaus G., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391 (1998) 591-594
23. Tamura N., Yoshida M., Ichikawa N., Handa M., Ikeda Y., Tanabe T., et al. Shear-induced von Willebrand factor-mediated platelet surface translocation of the CD40 ligand. Thromb Res 108 (2002) 311-315
24. Mach F., Schonbeck U., Sukhova G.K., Atkinson E., and Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394 (1998) 200-203
25. Schonbeck U., Sukhova G.K., Shimizu K., Mach F., and Libby P. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A 97 (2000) 7458-7463
26. Cipollone F., Ferri C., Desideri G., Paloscia L., Materazzo G., Mascellanti M., et al. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation 108 (2003) 2776-2782
27. Melter M., Reinders M.E., Sho M., Pal S., Geehan C., Denton M.D., et al. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood 96 (2000) 3801-3808
28. Schonbeck U., Sukhova G.K., Graber P., Coulter S., and Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 155 (1999) 1281-1291
29. Majima M., Hayashi I., Muramatsu M., Katada J., Yamashina S., and Katori M. Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol 130 (2000) 641-649
30. Garlichs C.D., John S., Schmeisser A., Eskafi S., Stumpf C., Karl M., et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 104 (2001) 2395-2400
31. Varo N., de Lemos J.A., Libby P., Morrow D.A., Murphy S.A., Nuzzo R., et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 108 (2003) 1049-1052
32. Ross R. The pathogenesis of atherosclerosis-an update. N Engl J Med 314 (1986) 488-500
33. Lim H.S., Blann A.D., and Lip G.Y. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation 109 (2004) 2524-2528
34. Nannizzi-Alaimo L., Alves V.L., and Phillips D.R. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 107 (2003) 1123-1128
35. Hermann A., Rauch B.H., Braun M., Schror K., and Weber A.A. Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 12 (2001) 74-82
36. Petrkova J., Szotkowska J., Hermanova Z., Lukl J., and Petrek M. Monocyte chemoattractant protein-1 in patients with peripheral arterial disease. Mediators Inflamm 13 (2004) 39-43
37. Erren M., Reinecke H., Junker R., Fobker M., Schulte H., Schurek J.O., et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 19 (1999) 2355-2363
38. Fiotti N., Giansante C., Ponte E., Delbello C., Calabrese S., Zacchi T., et al. Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis 145 (1999) 51-60
39. Lee W.L., Sheu W.H., Liu T.J., Lee W.J., Tsao C.R., Ju Y.H., et al. The short-/intermediate-term changes in novel vascular inflammatory markers after angioplasty plus stenting in patients with symptomatic advanced systemic arterial diseases. Atherosclerosis 176 (2004) 125-132